Viking Therapeutics (VKTX) Accounts Payables (2014 - 2026)

Viking Therapeutics has disclosed Accounts Payables across 13 years of filings, most recently posting $67.2 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $67.2 million, up 772.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $67.2 million (up 772.28% YoY), and the FY2025 annual result was $53.3 million, up 442.66% from the prior year.
• Accounts Payables came in at $67.2 million for Q1 2026 at Viking Therapeutics, up from $53.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $67.2 million in Q1 2026 to a low of $254000.0 in Q3 2024.
• The 5-year median for Accounts Payables is $5.7 million (2023), against an average of $12.2 million.
• Across the five-year window, Accounts Payables plunged 95.55% in 2024 and surged 1637.4% in 2025, its largest moves.
• Viking Therapeutics' Accounts Payables stood at $8.5 million in 2022, then slipped by 11.92% to $7.5 million in 2023, then soared by 30.63% to $9.8 million in 2024, then soared by 442.66% to $53.3 million in 2025, then rose by 26.16% to $67.2 million in 2026.
• The last three Accounts Payables figures came in at $67.2 million (Q1 2026), $53.3 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.